Any feedback?
No. of entries
Information on EC 3.4.21.122 - transmembrane protease serine 2
for references in articles please use BRENDA:EC3.4.21.122
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree 3 Hydrolases
3.4 Acting on peptide bonds (peptidases)
3.4.21 Serine endopeptidases
3.4.21.122 transmembrane protease serine 2
IUBMB Comments
The enzyme, present in mammalia, cleaves and inactivates EC 3.4.17.23, angiotensin-converting enzyme 2 (ACE2), at arginine residues in the region R697 to R716, which enhances influenza and coronavirus uptake . The enzyme also cleaves and activates influenza and coronavirus spike glycoproteins and thus facilitates virus-cell membrane fusions. The cleavage of SARS-COV2 spike glycoprotein occurs between the S2 and S2′ site at SKPSKR/SFIEDL, while the cleavage of MERS-COV glycoprotein occurs at GSRSAR/SAIEDL.
The enzyme appears in viruses and cellular organisms
Reaction Schemes
showThe enzyme cleaves angiotensin-converting enzyme 2 (EC 3.4.17.23) and cleaves influenzea A and B virus and coronavirus spike glycoproteins at arginine residues.
Synonyms
transmembrane protease serine 2, transmembrane serine protease 2, epitheliasin, transmembrane protease/serine subfamily member 2, more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
epitheliasin
TMPRSS2
epitheliasin
-
-
-
-
TMPRSS2
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
The enzyme cleaves angiotensin-converting enzyme 2 (EC 3.4.17.23) and cleaves influenzea A and B virus and coronavirus spike glycoproteins at arginine residues.
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Boc-FSR-7-amido-4-methylcoumarin + H2O
Boc-FSR + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-Gln-Ala-Arg-MCA + H2O
Boc-Gln-Ala-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin + H2O
Boc-Leu-Gly-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-Phe-Gly-Arg-7-amido-4-methylcoumarin + H2O
Boc-Phe-Gly-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
Boc-Phe-Ser-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-QAR-7-amido-4-methylcoumarin + H2O
Boc-QAR 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-QGR-7-amido-4-methylcoumarin + H2O
Boc-QGR + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-RVRR-7-amido-4-methylcoumarin + H2O
Boc-RVRR + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
CH3-O-CO-D-cyclohexylalanine-Gly-Arg-4-nitroanilide + H2O
CH3-O-CO-D-cyclohexylalanine-Gly-Arg + 4-nitroaniline
Substrates: 58% of the activtiy with CH3-SO2-D-Arg-Gly-Arg-4-nitroanilide
Products: -
Products: -
?
CH3-SO2-D-Arg-Gly-Arg-4-nitroanilide + H2O
CH3-SO2-D-Arg-Gly-Arg + 4-nitroaniline
Substrates: -
Products: -
Products: -
?
CH3-SO2-D-Arg-Pro-Arg-7-amido-4-methylcoumarin + H2O
CH3-SO2-D-Arg-Pro-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
CH3-SO2-D-cyclohexylalanine-Gly-Arg-4-nitroanilide + H2O
CH3-SO2-D-cyclohexylalanine-Gly-Arg-4-nitroaniline
Substrates: 54% of the activtiy with CH3-SO2-D-Arg-Gly-Arg-4-nitroanilide
Products: -
Products: -
?
CH3-SO2-D-cyclohexylglycine-Gly-Arg-4-nitroanilide + H2O
CH3-SO2-D-cyclohexylglycine-Gly-Arg + 4-nitroaniline
Substrates: 70% of the activtiy with CH3-SO2-D-Arg-Gly-Arg-4-nitroanilide
Products: -
Products: -
?
D-cyclohexylalanine-Gly-Arg-4-nitroanilide + H2O
D-cyclohexylalanine-Gly-Arg + 4-nitroaniline
Substrates: -
Products: -
Products: -
?
D-hexahydrotyrosine-Gly-Arg-4-nitroanilide + H2O
D-hexahydrotyrosine-Gly-Arg + 4-nitroaniline
Substrates: 87% of the activtiy with CH3-SO2-D-Arg-Gly-Arg-4-nitroanilide
Products: -
Products: -
?
D-Phe-Pro-Arg-7-amido-4-methylcoumarin + H2O
D-Phe-Pro-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
gamma-subunit of epithelial sodium channel + H2O
?
Substrates: proteolytically activates the epithelial sodium channel (ENaC) by cleaving the gamma-subunit of the channel
Products: -
Products: -
?
hemagglutinin precursor HA0 + H2O
hemagglutinin HA1 + hemagglutinin HA2
Substrates: -
Products: -
Products: -
?
Tos-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
Tos-Gly-Pro-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Tos-Gly-Pro-Lys-7-amido-4-methylcoumarin + H2O
Tos-Gly-Pro-Lys + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
hemagglutinin precursor HA0 + H2O
?
-
Substrates: enzyme cleaves the heamglutinin precursor of influenza viruses recombinant vaccines Re-5, Re-6, and Re-9
Products: -
Products: -
?
hemagglutinin precursor HA0 + H2O
?
Substrates: hemagglutinin of influenza A virus and of influenza B virus
Products: -
Products: -
?
hemagglutinin precursor HA0 + H2O
hemagglutinin HA1 + ?
Substrates: -
Products: -
Products: -
?
hemagglutinin precursor HA0 + H2O
hemagglutinin HA1 + ?
Substrates: -
Products: -
Products: -
?
hemagglutinin precursor HA0 + H2O
hemagglutinin HA1 + ?
-
Substrates: -
Products: -
Products: -
?
SARS coronavirus spike protein + H2O
?
Substrates: -
Products: -
Products: -
?
SARS coronavirus spike protein + H2O
?
Substrates: -
Products: -
Products: -
?
additional information
?
-
Substrates: no substrate: laminin gamma1
Products: -
Products: -
?
additional information
?
-
Substrates: residue R667 of SARS spike protein, a trypsin cleavage site, is also required for S protein cleavage by TMPRSS2. TMPRSS2 and trypsin proteases cleave different SARS S glycoforms. R667 is required for SARS S cleavage by TMPRSS2, but is dispensable for TMPRSS2-mediated S protein activation. Residue R797, reported to be required for SARS S activation by trypsin, is dispensable for S protein cleavage but required for S protein activation by TMPRSS2
Products: -
Products: -
?
additional information
?
-
Substrates: the membrane fusion proteins of respiratory viruses often possess serine and glutamine residues at the P2 and P3 positions, respectively. These residues are not critical for cleavage by TMPRSS2
Products: -
Products: -
?
additional information
?
-
Substrates: TMPRSS2 is predicted to cleave after Lys or Arg residues since it contains Asp435 at the base of the specificity pocket (S1 subsite) that binds to the substrate
Products: -
Products: -
?
additional information
?
-
Substrates: at the P1 position, TMPRSS2 strongly prefers substrates with an arginine rather than a lysine. The P1' position may comprise a hydrophobic amino acid (isoleucine or valine) to bind to the large, hydrophobic S1 pocket of TMPRSS2
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
gamma-subunit of epithelial sodium channel + H2O
?
Substrates: proteolytically activates the epithelial sodium channel (ENaC) by cleaving the gamma-subunit of the channel
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
1-[(2R)-4-(4-benzylpiperazin-1-yl)-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
3-cyclohexyl-N-(phenylmethanesulfonyl)-D-alanyl-N-[(4-carbamimidoylphenyl)methyl]-N6-decanoyl-L-lysinamide
peptide mimetic inhibitor. Cleavage of HA0 and the spread of A/Hamburg/09 in TMPRSS2-expressing cells are strongly inhibited by the decanoylated inhibitor. Only low amounts of progeny virions are detected in supernatants of inhibitor-treated cells at 24 h p.i. due to the suppression of proteolytic activation of HA and thus the suppression of virus propagation
3-[(2S)-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-(4-[2-[(methylcarbamoyl)amino]ethyl]piperidin-1-yl)-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-2-[(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-(4-[2-[(methylcarbamoyl)amino]ethyl]piperidin-1-yl)-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
treatment of cells with 10 microM inhibitor causes a 10fold and 100fold reduction in virus titres of A/Hamburg H1N1 and A/Aichi H3N2 respectively, at 24 h
3-[(2S)-3-[4-[(cyclohexylcarbamoyl)amino]piperidin-1-yl]-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[(cyclohexylcarbamoyl)amino]piperidin-1-yl]-2-[(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2',3'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2'-chloro-4'-ethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2'-chloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2'-fluoro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(3',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(3'-fluoro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-chloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-ethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-fluoro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
-
4-[4-[([1-[3-carbamimidoyl-N-(2',3'-dichloro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(2'-chloro-4'-ethoxy[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(2'-fluoro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(3',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(3'-fluoro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
4-[4-[([1-[3-carbamimidoyl-N-(4'-fluoro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
-
5-oxo-N-(phenylmethanesulfonyl)-5-[4-(pyrimidin-2-yl)piperazin-1-yl]-D-norvalyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
5-[4-[(benzyloxy)carbonyl]piperazin-1-yl]-5-oxo-N-(phenylmethanesulfonyl)-D-norvalyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
benzyl 4-[(3R)-4-[(2S)-2-[[(4-carbamimidoylphenyl)methyl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-[(phenylmethanesulfonyl)amino]butanoyl]piperazine-1-carboxylate
-
bromhexine
treatment significantly reduces the migration and invasion phenotypes promoted by TMPRSS2-activated HGF
methyl 1-[3-carbamimidoyl-N-(naphthalene-2-sulfonyl)-L-phenylalanyl]piperidine-4-carboxylate
-
N-(3-[[(2S)-1-[4-(2-aminoethyl)piperidin-1-yl]-3-(3-carbamimidoylphenyl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(benzylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(cyclohexylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(ethylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(methylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(phenylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(benzylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(cyclohexylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(ethylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(methylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(phenylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[2-(carbamoylamino)ethyl]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
-
N-(phenylmethanesulfonyl)-4-carbamimidoyl-D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-4-cyano-D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-D-alanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-D-alpha-aspartyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-D-cyclohexylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-D-leucyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-D-valyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)-L-leucyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-(phenylmethanesulfonyl)glycyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-(morpholin-4-yl)-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-oxo-2-[(phenylmethanesulfonyl)amino]-4-(piperazin-1-yl)butanoyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-oxo-2-[(phenylmethanesulfonyl)amino]-4-[4-(propan-2-yl)piperazin-1-yl]butanoyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-oxo-2-[(phenylmethanesulfonyl)amino]-4-[4-(pyrimidin-2-yl)piperazin-1-yl]butanoyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-[4-(3,5-dimethylphenyl)piperazin-1-yl]-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
-
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
-
N-[3-([(2S)-3-(3-carbamimidoylphenyl)-1-[4-(carbamoylamino)piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl)phenyl]-beta-alaninamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-2-aminobutanoylamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-alaninamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-argininamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-isoleucinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-leucinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-norvalinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-phenylalaninamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-serinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-valinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]glycinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-D-arginyl-N6-[(benzyloxy)carbonyl]-N-[(4-carbamimidoylphenyl)methyl]-L-lysinamide
-
N2-(phenylmethanesulfonyl)-D-homoarginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-D-homophenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-D-lysyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-N-tert-butoxy-D-asparaginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-N6-(benzyloxycarbonyl)-D-lysyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
N2-(phenylmethanesulfonyl)-O-(tert-butyl)-D-glutamyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
-
Nafamostat
potent inhibitor of protein-mediated membrane fusion, blocks MERS-CoV infection in vitro
tert-butyl N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-alpha-asparaginate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000363
1-[(2R)-4-(4-benzylpiperazin-1-yl)-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000011
3-[(2S)-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-(4-[2-[(methylcarbamoyl)amino]ethyl]piperidin-1-yl)-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000013
3-[(2S)-2-[(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-(4-[2-[(methylcarbamoyl)amino]ethyl]piperidin-1-yl)-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000005
3-[(2S)-3-[4-[(cyclohexylcarbamoyl)amino]piperidin-1-yl]-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000003
3-[(2S)-3-[4-[(cyclohexylcarbamoyl)amino]piperidin-1-yl]-2-[(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000027
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2',3'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000009
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000001
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000078
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2'-chloro-4'-ethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000028
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(2'-fluoro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000089
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(3',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000072
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(3'-fluoro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000054 - 0.0000073
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-chloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
0.0000048
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-ethoxy[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000028
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-fluoro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000019
4-[4-[([1-[3-carbamimidoyl-N-(2',3'-dichloro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000004
4-[4-[([1-[3-carbamimidoyl-N-(2',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000045
4-[4-[([1-[3-carbamimidoyl-N-(2',4'-dimethoxy[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000017
4-[4-[([1-[3-carbamimidoyl-N-(2'-chloro-4'-ethoxy[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00004
4-[4-[([1-[3-carbamimidoyl-N-(2'-fluoro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000036
4-[4-[([1-[3-carbamimidoyl-N-(3',4'-dichloro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000207
4-[4-[([1-[3-carbamimidoyl-N-(3'-fluoro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000072
4-[4-[([1-[3-carbamimidoyl-N-(4'-fluoro[1,1'-biphenyl]-3-sulfonyl)-L-phenylalanyl]piperidin-4-yl]carbamoyl)amino]cyclohexyl]-N-methylbutanamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000821
5-oxo-N-(phenylmethanesulfonyl)-5-[4-(pyrimidin-2-yl)piperazin-1-yl]-D-norvalyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.001222
5-[4-[(benzyloxy)carbonyl]piperazin-1-yl]-5-oxo-N-(phenylmethanesulfonyl)-D-norvalyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000624
benzyl 4-[(3R)-4-[(2S)-2-[[(4-carbamimidoylphenyl)methyl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-[(phenylmethanesulfonyl)amino]butanoyl]piperazine-1-carboxylate
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00022
D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00009
D-homophenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00018
D-homophenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00002
D-homotyrosinyl-N-[(4-carbamimidoylphenyl)methyl]-L-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0029
D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00018
methyl 1-[3-carbamimidoyl-N-(naphthalene-2-sulfonyl)-L-phenylalanyl]piperidine-4-carboxylate
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000008
N-(3-[[(2S)-1-[4-(2-aminoethyl)piperidin-1-yl]-3-(3-carbamimidoylphenyl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000018
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(benzylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000022
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(cyclohexylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000011
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(ethylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00001
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(methylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000007
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-(4-[2-[(phenylcarbamoyl)amino]ethyl]piperidin-1-yl)-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000021
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(benzylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000006
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(cyclohexylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00041
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(ethylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000081
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(methylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000017
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[(phenylcarbamoyl)amino]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000016
N-(3-[[(2S)-3-(3-carbamimidoylphenyl)-1-[4-[2-(carbamoylamino)ethyl]piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl]phenyl)-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000123
N-(phenylmethanesulfonyl)-4-carbamimidoyl-D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000706
N-(phenylmethanesulfonyl)-4-cyano-D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.001637
N-(phenylmethanesulfonyl)-D-alanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.007344
N-(phenylmethanesulfonyl)-D-alpha-aspartyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000335
N-(phenylmethanesulfonyl)-D-cyclohexylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000393
N-(phenylmethanesulfonyl)-D-leucyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000166
N-(phenylmethanesulfonyl)-D-phenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000322
N-(phenylmethanesulfonyl)-D-valyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.001633
N-(phenylmethanesulfonyl)glycyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000101
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-(morpholin-4-yl)-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000045
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-oxo-2-[(phenylmethanesulfonyl)amino]-4-(piperazin-1-yl)butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000244
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-oxo-2-[(phenylmethanesulfonyl)amino]-4-[4-(propan-2-yl)piperazin-1-yl]butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000838
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-oxo-2-[(phenylmethanesulfonyl)amino]-4-[4-(pyrimidin-2-yl)piperazin-1-yl]butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000417
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000111
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-[4-(3,5-dimethylphenyl)piperazin-1-yl]-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000248
N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-4-[4-[3-(dimethylamino)propyl]piperazin-1-yl]-4-oxo-2-[(phenylmethanesulfonyl)amino]butanoyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000074
N-[3-([(2S)-3-(3-carbamimidoylphenyl)-1-[4-(carbamoylamino)piperidin-1-yl]-1-oxopropan-2-yl]sulfamoyl)phenyl]-beta-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000052
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-2-aminobutanoylamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000018
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-alaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000025
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-argininamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000499
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-isoleucinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000272
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-leucinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000068
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-norvalinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00021
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-phenylalaninamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000019
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000143
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-serinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000409
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-valinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000068
N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]glycinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00006
N2-(phenylmethanesulfonyl)-D-arginyl-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00005
N2-(phenylmethanesulfonyl)-D-arginyl-N6-[(benzyloxy)carbonyl]-N-[(4-carbamimidoylphenyl)methyl]-L-lysinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000021
N2-(phenylmethanesulfonyl)-D-homoarginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00005
N2-(phenylmethanesulfonyl)-D-homophenylalanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00002
N2-(phenylmethanesulfonyl)-D-lysyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000019
N2-(phenylmethanesulfonyl)-N-tert-butoxy-D-asparaginyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000184
N2-(phenylmethanesulfonyl)-N6-(benzyloxycarbonyl)-D-lysyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.00023
N2-(phenylmethanesulfonyl)-O-(tert-butyl)-D-glutamyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.000738
tert-butyl N2-(phenylmethanesulfonyl)-D-arginyl-N-[(4-carbamimidoylphenyl)methyl]-L-alpha-asparaginate
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000054
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-chloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
0.0000073
3-[(2S)-3-[4-[2-([[4-(2-aminoethyl)cyclohexyl]carbamoyl]amino)ethyl]piperidin-1-yl]-2-[(4'-chloro[1,1'-biphenyl]-3-sulfonyl)amino]-3-oxopropyl]benzene-1-carboximidamide
50 mM Tris/HCl buffer, pH 8.0, 22°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
Tmprss2 and Tmprss4 are coexpressed in alveolar and bronchial regions
brenda
Tmprss2 and Tmprss4 are coexpressed in alveolar and bronchial regions
brenda
expression is highest in ciliated cells and type I alveolar epithelial cells (AT1)
brenda
immunoreactive cells are found in 3 days old but not in 1-month-old male rats
brenda
Tmprss2 and Tmprss4 are coexpressed in alveolar and bronchial regions
brenda
immunoreactive cells are found in 3 days old but not in 1-month-old male rats
brenda
TMPRSS2 protein is present, TMPRSS2 mRNA is not present
brenda
immunoreactive cells are found in 3 days old but not in 1-month-old male rats
brenda
immunoreactive cells are found in 3 days old but not in 1-month-old male rats
brenda
periodontitis increases TMPRSS2 expression in the cell membrane of gingival keratinocytes
brenda